Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment
- 31 August 2006
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 71 (1), 42-52
- https://doi.org/10.1016/j.antiviral.2006.02.008
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavirAntiviral Research, 2005
- Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressureAIDS, 2004
- Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptaseJournal of Virology, 2004
- Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected AdultsJournal of Virology, 2002
- Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutationsJournal of Medical Virology, 2001
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000
- Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug usersAIDS, 1999
- HIV-1 protease inhibitors. A review for cliniciansJAMA, 1997
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Construction of Phylogenetic TreesScience, 1967